Arteraai company information, Employees & Contact Information

Artera Receives U.S. FDA De Novo Marketing Authorization for AI-Digital Pathology Software Revolutionizing Prostate Cancer Care Business Wire

Study to evaluate impact of ArteraAI on clinical decision-making for prostate cancer Urology Times

Why Artera's CEO is bullish on AI agents to revamp patient communications Fierce Healthcare

FDA Grants Breakthrough Device Designation for Artera's AI-Powered Software for Prostate Cancer Care Imaging Technology News

Multimodal AI Test Predicts Prostate Cancer Metastasis and Treatment Response - Timothy Showalter UroToday

How Marc Benioff paired experts in AI and prostate cancer, leading to a new way to fine-tune treatments The Business Journals

Artera gets FDA de novo nod for AI prostate cancer prognosis tool Mobi Health News

Artera’s AI-Powered Software for Prostate Cancer Earns FDA Breakthrough Nod Medical Product Outsourcing

FDA Okays AI-Based Prostate Cancer Risk-Stratification Tool Medscape

Why 100+ Providers Are Using Artera’s AI Agents for Patient Communication MedCity News

Artera Launches Real-World Registry to Track AI’s Impact in Cancer Care HIT Consultant

External validation of a digital pathology-based multimodal artificial intelligence-derived prognostic model in patients with advanced prostate cancer starting long-term androgen deprivation therapy: a post-hoc ancillary biomarker study of four phase 3 randomi The Lancet

FDA grants de novo authorization to ArteraAI Prostate Urology Times

U.S. FDA Grants Artera Breakthrough Device Designation for AI-Powered Software Transforming Prostate Cancer Care Business Wire

Artera receives FDA Breakthrough Designation for AI prostate test Mobi Health News

Artera Launches Registry Trial to Measure Real-World Impact and Outcomes of its Prostate Test Business Wire

Phase 3 trial launches ArteraAI Prostate Test for treatment selection Urology Times

Artera Achieves Nationwide Access for its ArteraAI Prostate Test with New York State License Business Wire

Artera Announces Collaboration with Tempus to Expand Access to Personalized Prostate Cancer Treatment Business Wire

The ArteraAI Prostate Test Enhanced with New Insights for Higher Risk Patients with Localized Prostate Cancer Business Wire

Utilizing AI Precision Medicine to Best Choose Prostate Cancer Therapy Cure Today

Artera Presenting Validation Data at 2025 ASCO Annual Meeting Highlighting How Multimodal AI Platform (MMAI) is Advancing Personalized Cancer Care Business Wire

Tempus Partners with Artera to Expand Personalized Prostate Cancer Treatment Inside Precision Medicine

Artera partners with Tempus to expand AI cancer test access Medical Device Network

FDA grants de novo authorisation to Artera’s prostate software Medical Device Network

Artera Harmony Co-Pilots Demonstrate Proven Success with 100+ Healthcare Providers PR Newswire

Andre Esteva: 40 Under 40 2025 Modern Healthcare News

ASCO 2025: AI test determines best prostate cancer treatment – which could save NHS money The Institute of Cancer Research

Artera gets FDA okay for prostate cancer AI pharmaphorum

Artera Unveils Four Presentations at ASTRO 2025 Illustrating its Multimodal Artificial Intelligence (MMAI) Platform’s Scalability, Speed, and Potential to Personalize Treatment Decisions for Multiple Cancers Business Wire

AI test to determine best prostate cancer treatment could save lives and money | UCL News - UCL University College London

Artera Announces 1st Patient Enrolled in PROSTATE-IQ Trial to Reduce Burden of Hormone Therapy in Men with Prostate Cancer Recurrence After Prostatectomy BioSpace

Artera Celebrates Industry Recognitions and Leadership Promotions PR Newswire

Artera’s Multimodal Artificial Intelligence Named Among TIME's 2024 Best Inventions Business Wire

ArteraAI Multimodal Artificial Intelligence: the 200 Best Inventions of 2024 Time Magazine

Artera unveils AI co-pilots to ease patient communication headaches Fierce Healthcare

NCCN Recommends First AI Prognostic Tool in Prostate Cancer Targeted Oncology

Predicting Response to Hormone Therapy in Prostate Cancer With a Post-Prostatectomy MMAI Model - Todd Morgan UroToday

John Theurer Cancer Center First in the Country to Evaluate New AI Technology Assessing Aggressiveness of Prostate Cancer Post Surgery Hackensack Meridian Health

Artera Receives California Lab License, Expanding Access to its ArteraAI Prostate Test Business Wire

ArteraAI Secures $20 Million in Funding to Further Personalize Cancer Therapy With Multimodal AI Business Wire

The Artera AI Model: Advancing Personalized Medicine in Prostate Cancer Treatment | Dan Spratt & Alicia Morgans Discuss NEJM Evidence Manuscript UroToday

ArteraAI test expands to inform decisions for active surveillance in prostate cancer Urology Times

Artera secures California licence for AI-based prostate test Medical Device Network

Artera Announces Three Presentations at ASCO 2024 That Demonstrate the Reliability and Depth of its AI Cancer Platform Business Wire

Artera Launches with $90 Million in Funding to Personalize Cancer Therapy With Multimodal AI Business Wire

ArteraAI Prostate Test included in NCCN guidelines Urology Times

Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials Nature

Artera Multi-Modal AI Platform - Guiding Treatment Decisions in Men with Prostate Cancer - Andre Esteva & Felix Feng UroToday

CMS Okays Payment for Novel AI Prostate Test Medscape

Dr. McKay highlights the ArteraAI Prostate Test Urology Times

Who is ARTERA? - Andre Esteva UroToday

ArteraAI and GenesisCare Partner to Provide Precision Cancer Therapy to Patients with Localized Prostate Cancer In Australia Business Wire

Cancer-Testing Startup Artera Raises $90M Crunchbase News

Artera Announces New AI Products and Harmony Platform Enhancements PR Newswire

How AI Can Make Cancer Treatment More Equitable Time Magazine

Artera Unveils Two New AI Patient Engagement Copilots HIT Consultant

Beyond Genomics: AI Informing Decision Making in Prostate Cancer – Ashley Ross UroToday

Artera Raises $90 Million in Funding The SaaS News

ArteraAI Raises $20 Million in Funding The SaaS News

Artera Launches with $90M for Multimodal AI, Predictive Cancer Tests HIT Consultant

Artera Continues to Expand Executive Team & Attract Top Talent PR Newswire